Home » Healthcare » Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market By Route of administration (Oral, Inhalation) By Drug class (Bronchodilators, Beta 2-Agonists, Anticholinergics, Theophyllines, Phosphodiesterase Type 4 Inhibitors, Steroids, Others)-Growth, Future Prospects & Competitive Analysis, 2016 – 2030

Summary
Table Of Content

Key Highlights of the Report

The global chronic obstructive pulmonary disease (COPD) treatment market is segmented by drug class, route of administration, distribution channel, and region. The bronchodilators segment is the most popular drug class segment, while inhalation is the route of administration segment leading market. Hospital Pharmacies is the distribution channel segment, with Asia-pacific leading the market growth.

The global chronic obstructive pulmonary disease (COPD) treatment market has been driven by several factors, such as the increasing prevalence of COPD globally, particularly among the aging population & advancements in medical technologies and drug development, such as bronchodilators, anti-inflammatory drugs, and oxygen therapy. However, the market also faces significant challenges; complex nature of COPD requires a multidimensional approach to treatment, including smoking cessation, pulmonary rehabilitation, and comorbidity management.

Nonetheless, the global Chronic obstructive pulmonary disease (COPD) treatment market offers significant growth opportunities, such as increasing focus on personalized medicine and precision therapies, opening doors for targeted treatment approaches in COPD management & growing adoption of digital health solutions and telemedicine.

Market Overview

The global Chronic obstructive pulmonary disease (COPD) treatment market has witnessed steady growth in recent years and is expected to grow at a CAGR of 4.70% between 2023 and 2030. The market was valued at USD 20.3 billion in 2022 and is expected to reach USD 27.99772927 billion in 2030.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

What Are the Main Drivers Of The Global Chronic obstructive pulmonary disease (COPD) treatment Market?

The global Chronic obstructive pulmonary disease (COPD) treatment market is driven by several factors, including the increasing prevalence of COPD globally, particularly among the aging population & advancements in medical technologies and drug development, such as bronchodilators, anti-inflammatory drugs, and oxygen therapy.

What Are the Major Challenges Faced by The Global Chronic obstructive pulmonary disease (COPD) treatment Market?

The global Chronic obstructive pulmonary disease (COPD) treatment market also faces several challenges; complex nature of COPD requires a multidimensional approach to treatment, including smoking cessation, pulmonary rehabilitation, and comorbidity management.

What Are the Growth Opportunities in The Global Chronic obstructive pulmonary disease (COPD) treatment Market?

The global chronic obstructive pulmonary disease (COPD) treatment market offers significant growth opportunities, such as increasing focus on personalized medicine and precision therapies, opening doors for targeted treatment approaches in COPD management & growing adoption of digital health solutions and telemedicine.

Executive Summary

Overview of the Global Chronic obstructive pulmonary disease (COPD) treatment market

The global Chronic obstructive pulmonary disease (COPD) treatment market has been steadily growing in recent years due to the increasing prevalence of COPD globally, particularly among the aging population & advancements in medical technologies and drug development, such as bronchodilators, anti-inflammatory drugs, and oxygen therapy.

Market Definition

The global chronic obstructive pulmonary disease (COPD) treatment market refers to the market for medical products and therapies aimed at managing and treating COPD, a chronic respiratory condition characterized by airflow obstruction. This includes a wide range of treatment options, such as bronchodilators, anti-inflammatory drugs, oxygen therapy, and pulmonary rehabilitation programs. The market encompasses pharmaceuticals, medical devices, and healthcare services related to COPD treatment. With a focus on improving symptoms, slowing disease progression, and enhancing quality of life for COPD patients, the market encompasses various interventions and approaches to address the complex nature of COPD and its associated challenges.

Market Insights

The global demand for Chronic obstructive pulmonary disease (COPD) treatment was valued at USD 20.3 Billion in 2022 and is expected to reach USD 27.99772927 Billion in 2030, growing at a CAGR of 4.70% between 2023 and 2030.
Bronchodilators are the leading drug class base segment and held more than three-firth of the share in terms of value in 2022, while the anticholinergics segment is likely to exhibit the fastest CAGR during the forecast period.
Hospital Pharmacies are the leading distribution channel-based segment expected to post the highest CAGR during the forecast period & leading the market share with more than 35% share in 2022.
Inhalation is the most demanded route of the administration segment that is expected to rise with maximum CAGR with nearly two-thirds of the share
Asia-pacific is fueling the growth of the Chronic obstructive pulmonary disease (COPD) treatment industry with a nearly a two-thirds share in 2022, while Europe and North America collectively accounted for just nearly 55% share in 2022. Europe held more than 30% share in 2022.

The major driver that drives the market is the increasing prevalence of COPD globally, particularly among the aging population & advancements in medical technologies and drug development, such as bronchodilators, anti-inflammatory drugs, and oxygen therapy.
At the same time, high costs associated with COPD treatment, including medication, hospitalization, and long-term care & lack of awareness and underdiagnosis of COPD, and limited access to healthcare facilities, especially in rural areas, are the main restraints.
Rising focus on personalized medicine and precision therapies opens doors for targeted treatment approaches in COPD management & growing adoption of digital health solutions and telemedicine as the major opportunities in the market.

Segmentation by Drug class

Bronchodilators route of administration is the leading segment and holds more than three-firth of the share in terms of value.

Anticholinergics will likely exhibit the fastest CAGR during the forecast period.

Segmentation by Route of Administration

The inhalation drug class is the leading segment and holds more than two-thirds of the share in terms of value.
Oral contributes to the rest of the demand for Chronic obstructive pulmonary disease (COPD) treatment market.

Segmentation by Distribution channel

Hospital Pharmacies segment governs the demand for the Chronic obstructive pulmonary disease (COPD) treatment industry in the world, holding held more than 35% share in 2022
The online Pharmacies segment contributes to the rest of the demand for the chronic obstructive pulmonary disease (COPD) treatment market.

Segmentation by Region

Asia-pacific was fueling the growth of the Chronic obstructive pulmonary disease (COPD) treatment industry with a nearly two-third share in 2022.
Asia-pacific and Europe collectively account for nearly under 55% share in 2022, with Europe held more than 30% share in 2022.
The rest of the world, including Latin America, The Middle East, and Africa, contributes the remainder to the demand for Chronic obstructive pulmonary disease (COPD) treatment.

The growing prevalence of COPD globally, particularly among the aging population & advancements in medical technologies and drug development, such as bronchodilators, anti-inflammatory drugs, and oxygen therapy, drive the market. However, the market is restrained by lack of awareness and underdiagnosis of COPD and limited access to healthcare facilities, especially in rural areas.

In Japan, there is a growing prevalence of COPD in the country, primarily driven by an aging population and a high smoking rate. This increase in the number of COPD patients necessitates expanded treatment options and resources. There is a rising awareness and recognition of COPD as a significant public health issue in Japan. This has led to increased efforts in early diagnosis, screening programs, and public education campaigns, resulting in more individuals seeking medical attention and treatment for COPD.

Brazil has advancements in medical technologies and therapeutic options have expanded the range of treatment choices available to COPD. This includes the development of innovative medications, inhalation devices, and pulmonary rehabilitation programs, which contribute to the overall growth of the COPD treatment market. Furthermore, government initiatives and healthcare policies in Brazil are focused on improving COPD management and patient outcomes. These efforts include the implementation of preventive measures, smoking cessation programs, and increased access to healthcare services for COPD patients.

Increasing Prevalence of chronic obstructive pulmonary disease (COPD)

The chronic obstructive pulmonary disease (COPD) epidemic is one of the main factors propelling the development of the COPD treatment market. A progressive respiratory condition called COPD impairs breathing by obstructing airflow. According to a study published in the Jornal Brasileiro de Pneumologia, COPD prevalence in Brazil has been steadily increasing. The study found that the prevalence of COPD among adults aged 40 years or older rose from 7.8% in 2003 to 13.6% in 2017. This significant increase in COPD cases in Brazil underscores the need for effective treatments and interventions.

Technological Advancements and Innovative Treatments

Technological advancements and innovative treatments in the field of COPD contribute significantly to the growth of the COPD treatment industry. These advancements aim to provide more effective and targeted therapies, improve patient outcomes, and enhance the overall management of COPD. The management of COPD may change as a result of the incorporation of digital health technologies like telemedicine and remote patient monitoring. These technologies enable real-time monitoring of symptoms, remote consultations with healthcare providers, and personalized care plans. News reports frequently highlight the implementation of telehealth platforms and mobile applications for COPD management, showcasing the adoption of digital solutions to enhance patient care.

high cost associated with chronic obstructive pulmonary disease (COPD) treatment

The expenses incurred in managing COPD can be substantial, including medication costs, hospitalizations, pulmonary rehabilitation, and long-term care. This poses a challenge, particularly in regions with limited healthcare resources and populations with lower incomes. A study published in the Annals of the American Thoracic Society highlighted the financial burden faced by COPD patients in the United States. The study revealed that COPD patients had higher healthcare costs compared to those without COPD. The costs included hospitalizations, emergency department visits, prescription medications, and outpatient care, resulting in a significant economic burden on individuals and the healthcare system.

Personalized Medicine and Precision Therapies

Personalized medicine aims to tailor treatment approaches based on an individual’s specific characteristics, including genetic, molecular, and environmental factors. Precision therapies target specific molecular pathways or mechanisms involved in COPD, allowing for more targeted and effective interventions. Advancements in inhalation devices and drug delivery systems provide opportunities for personalized treatment options. For instance, the development of smart inhalers with built-in sensors can track medication adherence and provide feedback to patients, optimizing treatment effectiveness. Furthermore, the availability of a variety of inhaler types and formulations enables medical professionals to choose the best tool and drug for each patient, improving treatment outcomes.

Competitive Landscape

Key Players

The global Chronic obstructive pulmonary disease (COPD) treatment market is highly competitive, with the presence of several key players. Some of the major players in the market and their market share are as follows:

AstraZeneca Plc
Orion Corporation
Mylan N.V.
Boehringer Ingelheim
Teva Pharmaceutical Industries Ltd.
GlaxoSmithKline plc
Novartis AG
Sunovion Pharmaceuticals, Inc.
CHIESI Farmaceutici SpA.

These companies focus on the route of administration innovation, expanding their distribution channel, mergers, and acquisitions to stay ahead in the market.

The major players in the global Chronic obstructive pulmonary disease (COPD) treatment market constantly strive to stay ahead by introducing new routes of administration and innovations.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Summary of Key Findings

Rising prevalence of COPD globally, particularly among the aging population & advancements in medical technologies and drug development, such as bronchodilators, anti-inflammatory drugs, and oxygen therapy driving market growth.

Market segmented by drug class, route of administration, distribution channel, and region.
Bronchodilators are the most popular drug class segment, with anticholinergics drug class as the primary route of administration segment.
Inhalation is the most common route of administration segment.
The hospital Pharmacies segment governs the demand for the Chronic obstructive pulmonary disease (COPD) treatment industry.
Asia-pacific is leading market growth; the market is highly competitive with key players including AstraZeneca Plc, Orion Corporation, Mylan N.V., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Boehringer Ingelheim, Novartis AG, and others.

Future Outlook

Positive outlook for the global chronic obstructive pulmonary disease (COPD) treatment market with significant growth potential in the Asia-pacific region

Increasing prevalence of COPD globally, particularly among the aging population & advancements in medical technologies and drug development, such as bronchodilators, anti-inflammatory drugs, and oxygen therapy drive growth
Challenges such as the complex nature of COPD require a multidimensional approach to treatment, including smoking cessation, pulmonary rehabilitation, and comorbidity management.

Segmentation

By Route of administration
- Oral
- Inhalation
By Drug class
- Bronchodilators
- Beta 2-Agonists
- Anticholinergics
- Theophyllines
- Phosphodiesterase Type 4 Inhibitors
- Steroids
- Others
By Distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region

North America
- US
- Canada
- Mexico
Europe
- Germany
- France
- The U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Data Modelling
1.3.2.1. Company Share Analysis Model
1.3.2.2. Revenue Based Modelling
1.3.3. Phase III – Primary Research
1.3.4. Research Limitations
1.3.5. Assumptions
1.4. Market Introduction
1.5. Market Research Scope

2. Executive Summary
2.1. Market Snapshot: Global Chronic obstructive pulmonary disease (COPD) treatment Market
2.2. Global Chronic obstructive pulmonary disease (COPD) treatment Market, By Drug Class
2.3. Global Chronic obstructive pulmonary disease (COPD) treatment Market, By Route of Administration
2.4. Global Chronic obstructive pulmonary disease (COPD) treatment Market, By Distribution Channel
2.5. Global Chronic obstructive pulmonary disease (COPD) treatment Market, By Region

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Chronic obstructive pulmonary disease (COPD) treatment Market Value, 2017-2030, (US$ Bn)
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.2. Market Restraints
3.2.3. Market Opportunities
3.2.4. Major Industry Challenges
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. Distribution Channel
3.5.2. Drug Class
3.5.3. Route of Administration
3.5.4. Geography

4. Premium Insights
4.1. STAR (Situation, Task, Action, Results) Analysis
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers/Consumers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitute Types
4.2.5. Intensity of Competitive Rivalry
4.3. Key Market Trends
4.3.1. Demand Side Trends
4.3.2. Supply Side Trends
4.4. Value Chain Analysis
4.5. Technology Analysis
4.6. Analysis and Recommendations
4.7. Marketing Strategy Analysis
4.7.1. Direct Marketing
4.7.2. Indirect Marketing
4.7.3. Marketing Channel Development Trend

5. Market Positioning of Key Players, 2022
5.1. Company market share of key players, 2022
5.2. Competitive Benchmarking
5.3. Market Positioning of Key Vendors
5.4. Geographical Presence Analysis
5.5. Major Strategies Adopted by Key Players
5.5.1. Key Strategies Analysis
5.5.2. Mergers and Acquisitions
5.5.3. Partnerships
5.5.4. Product Launch
5.5.5. Geographical Expansion
5.5.6. Others

6. Economic Impact Analysis
6.1. Recession Impact
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Latin America
6.1.5. Middle East and Africa
6.2. Ukraine-Russia War Impact
6.2.1. North America
6.2.2. Europe
6.2.3. Asia Pacific
6.2.4. Latin America
6.2.5. Middle East and Africa
6.3. COVID-19 Impact Analysis
6.3.1. North America
6.3.2. Europe
6.3.3. Asia Pacific
6.3.4. Latin America
6.3.5. Middle East and Africa

7. Global Chronic obstructive pulmonary disease (COPD) treatment Market, By Route of Administration
7.1. Global Chronic obstructive pulmonary disease (COPD) treatment Market Overview, by Route of Administration
7.1.1. Global Chronic obstructive pulmonary disease (COPD) treatment Market Revenue Share, By Route of Administration, 2022 Vs 2030 (in %)
7.2. Oral
7.2.1. Global Chronic obstructive pulmonary disease (COPD) treatment Market, By Region, 2017-2030 (US$ Bn)
7.3. Inhalation
7.3.1. Global Chronic obstructive pulmonary disease (COPD) treatment Market, By Region, 2017-2030 (US$ Bn)

8. Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2030 (US$ Bn)
8.1. Global Chronic obstructive pulmonary disease (COPD) treatment Market Overview, by Drug Class
8.1.1. Global Chronic obstructive pulmonary disease (COPD) treatment Market, By Drug Class, 2022 vs 2030 (in%)
8.2. Bronchodilators
8.2.1. Global Chronic obstructive pulmonary disease (COPD) treatment Market, By Region, 2017-2030 (US$ Bn)
8.3. Beta 2-Agonists
8.3.1. Global Chronic obstructive pulmonary disease (COPD) treatment Market, By Region, 2017-2030 (US$ Bn)
8.4. Anticholinergics
8.4.1. Global Chronic obstructive pulmonary disease (COPD) treatment Market, By Region, 2017-2030 (US$ Bn)
8.5. Theophyllines
8.5.1. Global Chronic obstructive pulmonary disease (COPD) treatment Market, By Region, 2017-2030 (US$ Bn)
8.6. Phosphodiesterase Type 4 Inhibitors
8.6.1. Global Chronic obstructive pulmonary disease (COPD) treatment Market, By Region, 2017-2030 (US$ Bn)
8.7. Steroids
8.7.1. Global Chronic obstructive pulmonary disease (COPD) treatment Market, By Region, 2017-2030 (US$ Bn)
8.8. Others
8.8.1. Global Chronic obstructive pulmonary disease (COPD) treatment Market, By Region, 2017-2030 (US$ Bn)

9. Global Chronic obstructive pulmonary disease (COPD) treatment Market, By Distribution Channel
9.1. Global Chronic obstructive pulmonary disease (COPD) treatment Market Overview, by Distribution Channel
9.1.1. Global Chronic obstructive pulmonary disease (COPD) treatment Market, By Distribution Channel, 2022 vs 2030 (in %)
9.2. Hospital Pharmacies
9.2.1. Global Chronic obstructive pulmonary disease (COPD) treatment Market, By Region, 2017-2030 (US$ Bn)
9.3. Retail Pharmacies
9.3.1. Global Chronic obstructive pulmonary disease (COPD) treatment Market, By Region, 2017-2030 (US$ Bn)
9.4. Online Pharmacies
9.4.1. Global Chronic obstructive pulmonary disease (COPD) treatment Market, By Region, 2017-2030 (US$ Bn)

10. Global Chronic obstructive pulmonary disease (COPD) treatment Market, By Region
10.1. Global Chronic obstructive pulmonary disease (COPD) treatment Market Overview, by Region
10.1.1. Global Chronic obstructive pulmonary disease (COPD) treatment Market, By Region, 2022 vs 2030 (in%)
10.2. Distribution Channel
10.2.1. Global Chronic obstructive pulmonary disease (COPD) treatment Market, By Distribution Channel, 2017-2030 (US$ Bn)
10.3. Drug Class
10.3.1. Global Chronic obstructive pulmonary disease (COPD) treatment Market, By Drug Class, 2017-2030 (US$ Bn)
10.4. Route of Administration
10.4.1. Global Chronic obstructive pulmonary disease (COPD) treatment Market, By Route of Administration, 2017-2030 (US$ Bn)

11. North America Chronic obstructive pulmonary disease (COPD) treatment Market Analysis
11.1. North America Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2017-2030(US$ Bn)
11.1.1. Overview
11.1.2. SRC Analysis
11.2. North America Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2030(US$ Bn)
11.2.1. Overview
11.2.2. SRC Analysis
11.3. North America Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2017-2030(US$ Bn)
11.3.1. Overview
11.3.2. SRC Analysis
11.4. North America Chronic obstructive pulmonary disease (COPD) treatment Market, by Country, 2017-2030 (US$ Bn)
11.4.1. North America Chronic obstructive pulmonary disease (COPD) treatment Market, by Country, 2022 Vs 2030 (in%)
11.4.2. U.S.
11.4.2.1. U.S. Chronic obstructive pulmonary disease (COPD) treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.4.2.2. U.S. Chronic obstructive pulmonary disease (COPD) treatment, By Distribution Channel, 2017-2030 (US$ Bn)
11.4.2.3. U.S. Chronic obstructive pulmonary disease (COPD) treatment, By Drug Class, 2017-2030 (US$ Bn)
11.4.2.4. U.S. Chronic obstructive pulmonary disease (COPD) treatment, By Route of Administration, 2017-2030 (US$ Bn)
11.4.3. Canada
11.4.3.1. Canada Chronic obstructive pulmonary disease (COPD) treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.4.3.2. Canada Chronic obstructive pulmonary disease (COPD) treatment, By Distribution Channel, 2017-2030 (US$ Bn)
11.4.3.3. Canada Chronic obstructive pulmonary disease (COPD) treatment, By Drug Class, 2017-2030 (US$ Bn)
11.4.3.4. Canada Chronic obstructive pulmonary disease (COPD) treatment, By Route of Administration, 2017-2030 (US$ Bn)
11.4.4. Mexico
11.4.4.1. Mexico Chronic obstructive pulmonary disease (COPD) treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.4.4.2. Mexico Chronic obstructive pulmonary disease (COPD) treatment, By Distribution Channel, 2017-2030 (US$ Bn)
11.4.4.3. Mexico Chronic obstructive pulmonary disease (COPD) treatment, By Drug Class, 2017-2030 (US$ Bn)
11.4.4.4. Mexico Chronic obstructive pulmonary disease (COPD) treatment, By Route of Administration, 2017-2030 (US$ Bn)

12. Europe Chronic obstructive pulmonary disease (COPD) treatment Market Analysis
12.1. Europe Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2017-2030(US$ Bn)
12.1.1. Overview
12.1.2. SRC Analysis
12.2. Europe Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2030(US$ Bn)
12.2.1. Overview
12.2.2. SRC Analysis
12.3. Europe Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2017-2030(US$ Bn)
12.3.1. Overview
12.3.2. SRC Analysis
12.4. Europe Chronic obstructive pulmonary disease (COPD) treatment Market, by region, 2017-2030 (US$ Bn)
12.4.1. Europe Chronic obstructive pulmonary disease (COPD) treatment Market, by Country, 2022 Vs 2030 (in%)
12.4.2. Germany
12.4.2.1. Germany Chronic obstructive pulmonary disease (COPD) treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.4.2.2. Germany Chronic obstructive pulmonary disease (COPD) treatment, By Distribution Channel, 2017-2030 (US$ Bn)
12.4.2.3. Germany Chronic obstructive pulmonary disease (COPD) treatment, By Drug Class, 2017-2030 (US$ Bn)
12.4.2.4. Germany Chronic obstructive pulmonary disease (COPD) treatment, By Route of Administration, 2017-2030 (US$ Bn)
12.4.3. France
12.4.3.1. France Chronic obstructive pulmonary disease (COPD) treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.4.3.2. France Chronic obstructive pulmonary disease (COPD) treatment, By Distribution Channel, 2017-2030 (US$ Bn)
12.4.3.3. France Chronic obstructive pulmonary disease (COPD) treatment, By Drug Class, 2017-2030 (US$ Bn)
12.4.3.4. France Chronic obstructive pulmonary disease (COPD) treatment, By Route of Administration, 2017-2030 (US$ Bn)
12.4.4. UK
12.4.4.1. UK Chronic obstructive pulmonary disease (COPD) treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.4.4.2. UK Chronic obstructive pulmonary disease (COPD) treatment, By Distribution Channel, 2017-2030 (US$ Bn)
12.4.4.3. UK Chronic obstructive pulmonary disease (COPD) treatment, By Drug Class, 2017-2030 (US$ Bn)
12.4.4.4. UK Chronic obstructive pulmonary disease (COPD) treatment, By Route of Administration, 2017-2030 (US$ Bn)
12.4.5. Italy
12.4.5.1. Italy Chronic obstructive pulmonary disease (COPD) treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.4.5.2. Italy Chronic obstructive pulmonary disease (COPD) treatment, By Distribution Channel, 2017-2030 (US$ Bn)
12.4.5.3. Italy Chronic obstructive pulmonary disease (COPD) treatment, By Drug Class, 2017-2030 (US$ Bn)
12.4.5.4. Italy Chronic obstructive pulmonary disease (COPD) treatment, By Route of Administration, 2017-2030 (US$ Bn)
12.4.6. Spain
12.4.6.1. Spain Chronic obstructive pulmonary disease (COPD) treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.4.6.2. Spain Chronic obstructive pulmonary disease (COPD) treatment, By Distribution Channel, 2017-2030 (US$ Bn)
12.4.6.3. Spain Chronic obstructive pulmonary disease (COPD) treatment, By Drug Class, 2017-2030 (US$ Bn)
12.4.6.4. Spain Chronic obstructive pulmonary disease (COPD) treatment, By Route of Administration, 2017-2030 (US$ Bn)
12.4.7. Rest of Europe
12.4.7.1. Rest of Europe Chronic obstructive pulmonary disease (COPD) treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.4.7.2. Rest of Europe Chronic obstructive pulmonary disease (COPD) treatment, By Distribution Channel, 2017-2030 (US$ Bn)
12.4.7.3. Rest of Europe Chronic obstructive pulmonary disease (COPD) treatment, By Drug Class, 2017-2030 (US$ Bn)
12.4.7.4. Rest of Europe Chronic obstructive pulmonary disease (COPD) treatment, By Route of Administration, 2017-2030 (US$ Bn)

13. Asia Pacific Chronic obstructive pulmonary disease (COPD) treatment Market Analysis
13.1. Asia Pacific Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2017-2030(US$ Bn)
13.1.1. Overview
13.1.2. SRC Analysis
13.2. Asia Pacific Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2030(US$ Bn)
13.2.1. Overview
13.2.2. SRC Analysis
13.3. Asia Pacific Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2017-2030(US$ Bn)
13.3.1. Overview
13.3.2. SRC Analysis
13.4. Asia Pacific Chronic obstructive pulmonary disease (COPD) treatment Market, by Country, 2017-2030 (US$ Bn)
13.4.1. Asia Pacific Chronic obstructive pulmonary disease (COPD) treatment Market, by Country, 2022 Vs 2030 (in%)
13.4.2. China
13.4.2.1. China Chronic obstructive pulmonary disease (COPD) treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.4.2.2. China Chronic obstructive pulmonary disease (COPD) treatment, By Distribution Channel, 2017-2030 (US$ Bn)
13.4.2.3. China Chronic obstructive pulmonary disease (COPD) treatment, By Drug Class, 2017-2030 (US$ Bn)
13.4.2.4. China Chronic obstructive pulmonary disease (COPD) treatment, By Route of Administration, 2017-2030 (US$ Bn)
13.4.3. Japan
13.4.3.1. Japan Chronic obstructive pulmonary disease (COPD) treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.4.3.2. Japan Chronic obstructive pulmonary disease (COPD) treatment, By Distribution Channel, 2017-2030 (US$ Bn)
13.4.3.3. Japan Chronic obstructive pulmonary disease (COPD) treatment, By Drug Class, 2017-2030 (US$ Bn)
13.4.3.4. Japan Chronic obstructive pulmonary disease (COPD) treatment, By Route of Administration, 2017-2030 (US$ Bn)
13.4.4. India
13.4.4.1. India Chronic obstructive pulmonary disease (COPD) treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.4.4.2. India Chronic obstructive pulmonary disease (COPD) treatment, By Distribution Channel, 2017-2030 (US$ Bn)
13.4.4.3. India Chronic obstructive pulmonary disease (COPD) treatment, By Drug Class, 2017-2030 (US$ Bn)
13.4.4.4. India Chronic obstructive pulmonary disease (COPD) treatment, By Route of Administration, 2017-2030 (US$ Bn)
13.4.5. South Korea
13.4.5.1. South Korea Chronic obstructive pulmonary disease (COPD) treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.4.5.2. South Korea Chronic obstructive pulmonary disease (COPD) treatment, By Distribution Channel, 2017-2030 (US$ Bn)
13.4.5.3. South Korea Chronic obstructive pulmonary disease (COPD) treatment, By Drug Class, 2017-2030 (US$ Bn)
13.4.5.4. South Korea Chronic obstructive pulmonary disease (COPD) treatment, By Route of Administration, 2017-2030 (US$ Bn)
13.4.6. South-East Asia
13.4.6.1. South-East Asia Chronic obstructive pulmonary disease (COPD) treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.4.6.2. South-East Asia Chronic obstructive pulmonary disease (COPD) treatment, By Distribution Channel, 2017-2030 (US$ Bn)
13.4.6.3. South-East Asia Chronic obstructive pulmonary disease (COPD) treatment, By Drug Class, 2017-2030 (US$ Bn)
13.4.6.4. South-East Asia Chronic obstructive pulmonary disease (COPD) treatment, By Route of Administration, 2017-2030 (US$ Bn)
13.4.7. Rest of Asia Pacific
13.4.7.1. Rest of Asia Pacific Chronic obstructive pulmonary disease (COPD) treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.4.7.2. Rest of Asia Pacific Chronic obstructive pulmonary disease (COPD) treatment, By Distribution Channel, 2017-2030 (US$ Bn)
13.4.7.3. Rest of Asia Pacific Chronic obstructive pulmonary disease (COPD) treatment, By Drug Class, 2017-2030 (US$ Bn)
13.4.7.4. Rest of Asia Pacific Chronic obstructive pulmonary disease (COPD) treatment, By Route of Administration, 2017-2030 (US$ Bn)

14. Latin America Chronic obstructive pulmonary disease (COPD) treatment Market Analysis
14.1. Latin America Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2017-2030(US$ Bn)
14.1.1. Overview
14.1.2. SRC Analysis
14.2. Latin America Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2030(US$ Bn)
14.2.1. Overview
14.2.2. SRC Analysis
14.3. Latin America Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2017-2030(US$ Bn)
14.3.1. Overview
14.3.2. SRC Analysis
14.4. Latin America Chronic obstructive pulmonary disease (COPD) treatment Market, by Country, 2017-2030 (US$ Bn)
14.4.1. Latin America Chronic obstructive pulmonary disease (COPD) treatment Market, by Country, 2022 Vs 2030 (in%)
14.4.2. Brazil
14.4.2.1. Brazil Chronic obstructive pulmonary disease (COPD) treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.4.2.2. Brazil Chronic obstructive pulmonary disease (COPD) treatment, By Distribution Channel, 2017-2030 (US$ Bn)
14.4.2.3. Brazil Chronic obstructive pulmonary disease (COPD) treatment, By Drug Class, 2017-2030 (US$ Bn)
14.4.2.4. Brazil Chronic obstructive pulmonary disease (COPD) treatment, By Route of Administration, 2017-2030 (US$ Bn)
14.4.3. Argentina
14.4.3.1. Argentina Chronic obstructive pulmonary disease (COPD) treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.4.3.2. Argentina Chronic obstructive pulmonary disease (COPD) treatment, By Distribution Channel, 2017-2030 (US$ Bn)
14.4.3.3. Argentina Chronic obstructive pulmonary disease (COPD) treatment, By Drug Class, 2017-2030 (US$ Bn)
14.4.3.4. Argentina Chronic obstructive pulmonary disease (COPD) treatment, By Route of Administration, 2017-2030 (US$ Bn)
14.4.4. Rest of Latin America
14.4.4.1. Rest of Latin America Chronic obstructive pulmonary disease (COPD) treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.4.4.2. Rest of Latin America Chronic obstructive pulmonary disease (COPD) treatment, By Distribution Channel, 2017-2030 (US$ Bn)
14.4.4.3. Rest of Latin America Chronic obstructive pulmonary disease (COPD) treatment, By Drug Class, 2017-2030 (US$ Bn)
14.4.4.4. Rest of Latin America Chronic obstructive pulmonary disease (COPD) treatment, By Route of Administration, 2017-2030 (US$ Bn)

15. Middle East and Africa Chronic obstructive pulmonary disease (COPD) treatment Market Analysis
15.1. Middle East and Africa Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2017-2030(US$ Bn)
15.1.1. Overview
15.1.2. SRC Analysis
15.2. Middle East and Africa Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2030(US$ Bn)
15.2.1. Overview
15.2.2. SRC Analysis
15.3. Middle East and Africa Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2017-2030(US$ Bn)
15.3.1. Overview
15.3.2. SRC Analysis
15.4. Middle East and Africa Chronic obstructive pulmonary disease (COPD) treatment Market, by Country, 2017-2030 (US$ Bn)
15.4.1. Middle East and Africa Chronic obstructive pulmonary disease (COPD) treatment Market, by Country, 2022 Vs 2030 (in%)
15.4.2. GCC Countries
15.4.2.1. GCC Countries Chronic obstructive pulmonary disease (COPD) treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
15.4.2.2. GCC Countries Chronic obstructive pulmonary disease (COPD) treatment, By Distribution Channel, 2017-2030 (US$ Bn)
15.4.2.3. GCC Countries Chronic obstructive pulmonary disease (COPD) treatment, By Drug Class, 2017-2030 (US$ Bn)
15.4.2.4. GCC Countries Chronic obstructive pulmonary disease (COPD) treatment, By Route of Administration, 2017-2030 (US$ Bn)
15.4.3. South Africa
15.4.3.1. South Africa Chronic obstructive pulmonary disease (COPD) treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
15.4.3.2. South Africa Chronic obstructive pulmonary disease (COPD) treatment, By Distribution Channel, 2017-2030 (US$ Bn)
15.4.3.3. South Africa Chronic obstructive pulmonary disease (COPD) treatment, By Drug Class, 2017-2030 (US$ Bn)
15.4.3.4. South Africa Chronic obstructive pulmonary disease (COPD) treatment, By Route of Administration, 2017-2030 (US$ Bn)
15.4.4. Rest of Middle East and Africa
15.4.4.1. Rest of Middle East and Africa Chronic obstructive pulmonary disease (COPD) treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
15.4.4.2. Rest of Middle East and Africa Chronic obstructive pulmonary disease (COPD) treatment, By Distribution Channel, 2017-2030 (US$ Bn)
15.4.4.3. Rest of Middle East and Africa Chronic obstructive pulmonary disease (COPD) treatment, By Drug Class, 2017-2030 (US$ Bn)
15.4.4.4. Rest of Middle East and Africa Chronic obstructive pulmonary disease (COPD) treatment, By Route of Administration, 2017-2030 (US$ Bn)

16. Company Profiles
16.1. Arkema SA
16.1.1. Company Overview
16.1.2. Deployments/Services Portfolio
16.1.3. Geographical Presence
16.1.4. Financial Summary
16.1.4.1. Market Revenue and Net Profit (2019-2022)
16.1.4.2. Business Segment Revenue Analysis
16.1.4.3. Geographical Revenue Analysis
16.2. APV Engineered Coatings, Inc.
16.3. Ashland Global Holdings, Inc.
16.4. BASF SE
16.5. Bayer AG
16.6. Elf Atochem S.A.
16.7. Fujian Blue Ocean & Black Stone Technology Co., Ltd.
16.8. FUJIFILM Wako Pure Chemical Corp.
16.9. Jesons Industries Ltd.
16.10. JSR Corp.
16.11. Kureha Corp.
16.12. Nexeon Ltd.
16.13. RotaLab Bilimsel Cihazlar Ltd.
16.14. SAMSUNG SDI CO., LTD.
16.15. Solvay SA
16.16. Targray Technology International Inc.
16.17. TDK Corp.
16.18. Trinseo SA
16.19. Ube Industries Ltd.
16.20. Zeon Corp.

List of Figures
FIG. 1 Global Chronic obstructive pulmonary disease (COPD) treatment Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Chronic obstructive pulmonary disease (COPD) treatment Market Segmentation
FIG. 4 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2022 (US$ Bn)
FIG. 5 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2022 (US$ Bn)
FIG. 6 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2022 (US$ Bn)
FIG. 7 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Geography, 2022 (US$ Bn)
FIG. 8 Attractive Investment Proposition, by Distribution Channel, 2022
FIG. 9 Attractive Investment Proposition, by Drug Class, 2022
FIG. 10 Attractive Investment Proposition, by Route of Administration, 2022
FIG. 11 Attractive Investment Proposition, by Geography, 2022
FIG. 12 Global Market Share Analysis of Key Chronic obstructive pulmonary disease (COPD) treatment Market Manufacturers, 2022
FIG. 13 Global Market Positioning of Key Chronic obstructive pulmonary disease (COPD) treatment Market Manufacturers, 2022
FIG. 14 Global Chronic obstructive pulmonary disease (COPD) treatment Market Value Contribution, By Route of Administration, 2022 & 2030 (Value %)
FIG. 15 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Oral, Value, 2017-2030 (US$ Bn)
FIG. 16 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Inhalation, Value, 2017-2030 (US$ Bn)
FIG. 17 Global Chronic obstructive pulmonary disease (COPD) treatment Market Value Contribution, By Drug Class, 2022 & 2030 (Value %)
FIG. 18 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Bronchodilators, Value, 2017-2030 (US$ Bn)
FIG. 19 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Beta 2-Agonists, 2017-2030 (US$ Bn)
FIG. 20 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Anticholinergics, Value, 2017-2030 (US$ Bn)
FIG. 21 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Theophyllines, 2017-2030 (US$ Bn)
FIG. 22 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Phosphodiesterase Type 4 Inhibitors, Value, 2017-2030 (US$ Bn)
FIG. 23 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Steroids, Value, 2017-2030 (US$ Bn)
FIG. 24 Global Chronic obstructive pulmonary disease (COPD) treatment Market Value Contribution, By Distribution Channel, 2022 & 2030 (Value %)
FIG. 25 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Hospital Pharmacies, Value, 2017-2030 (US$ Bn)
FIG. 26 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Retail Pharmacies, Value, 2017-2030 (US$ Bn)
FIG. 27 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Online Pharmacies, Value, 2017-2030 (US$ Bn)
FIG. 28 North America Chronic obstructive pulmonary disease (COPD) treatment Market, 2017-2030 (US$ Bn)
FIG. 29 U.S. Chronic obstructive pulmonary disease (COPD) treatment Market, 2017-2030 (US$ Bn)
FIG. 30 Canada Chronic obstructive pulmonary disease (COPD) treatment Market, 2017-2030 (US$ Bn)
FIG. 31 Europe Chronic obstructive pulmonary disease (COPD) treatment Market, 2017-2030 (US$ Bn)
FIG. 32 Germany Chronic obstructive pulmonary disease (COPD) treatment Market, 2017-2030 (US$ Bn)
FIG. 33 France Chronic obstructive pulmonary disease (COPD) treatment Market, 2017-2030 (US$ Bn)
FIG. 34 U.K. Chronic obstructive pulmonary disease (COPD) treatment Market, 2017-2030 (US$ Bn)
FIG. 35 Italy Chronic obstructive pulmonary disease (COPD) treatment Market, 2017-2030 (US$ Bn)
FIG. 36 Spain Chronic obstructive pulmonary disease (COPD) treatment Market, 2017-2030 (US$ Bn)
FIG. 37 Rest of Europe Chronic obstructive pulmonary disease (COPD) treatment Market, 2017-2030 (US$ Bn)
FIG. 38 Asia Pacific Chronic obstructive pulmonary disease (COPD) treatment Market, 2017-2030 (US$ Bn)
FIG. 39 China Chronic obstructive pulmonary disease (COPD) treatment Market, 2017-2030 (US$ Bn)
FIG. 40 Japan Chronic obstructive pulmonary disease (COPD) treatment Market, 2017-2030 (US$ Bn)
FIG. 41 India Chronic obstructive pulmonary disease (COPD) treatment Market, 2017-2030 (US$ Bn)
FIG. 42 South Korea Chronic obstructive pulmonary disease (COPD) treatment Market, 2017-2030 (US$ Bn)
FIG. 43 South-East Asia Chronic obstructive pulmonary disease (COPD) treatment Market, 2017-2030 (US$ Bn)
FIG. 44 Rest of Asia Pacific Chronic obstructive pulmonary disease (COPD) treatment Market, 2017-2030 (US$ Bn)
FIG. 45 Latin America Chronic obstructive pulmonary disease (COPD) treatment Market, 2017-2030 (US$ Bn)
FIG. 46 Brazil Chronic obstructive pulmonary disease (COPD) treatment Market, 2017-2030 (US$ Bn)
FIG. 47 Mexico Chronic obstructive pulmonary disease (COPD) treatment Market, 2017-2030 (US$ Bn)
FIG. 48 Rest of Latin America Chronic obstructive pulmonary disease (COPD) treatment Market, 2017-2030 (US$ Bn)
FIG. 49 Middle East & Africa Chronic obstructive pulmonary disease (COPD) treatment Market, 2017-2030 (US$ Bn)
FIG. 50 GCC Countries Chronic obstructive pulmonary disease (COPD) treatment Market, 2017-2030 (US$ Bn)
FIG. 51 South Africa Chronic obstructive pulmonary disease (COPD) treatment Market, 2017-2030 (US$ Bn)
FIG. 52 Rest of Middle East and Africa Chronic obstructive pulmonary disease (COPD) treatment Market, 2017-2030 (US$ Bn)

List of Tables
TABLE 1 Market Snapshot: Global Chronic obstructive pulmonary disease (COPD) treatment Market
TABLE 2 Global Chronic obstructive pulmonary disease (COPD) treatment Market: Market Drivers Impact Analysis
TABLE 3 Global Chronic obstructive pulmonary disease (COPD) treatment Market: Market Restraints Impact Analysis
TABLE 4 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Competitive Benchmarking, 2022
TABLE 5 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Geographical Presence Analysis, 2022
TABLE 6 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Key Strategies Analysis, 2022
TABLE 7 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Oral, By Region, 2017-2022 (US$ Bn)
TABLE 8 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Oral, By Region, 2023-2030 (US$ Bn)
TABLE 9 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Inhalation, By Region, 2017-2022 (US$ Bn)
TABLE 10 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Inhalation, By Region, 2023-2030 (US$ Bn)
TABLE 11 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Bronchodilators, By Region, 2017-2022 (US$ Bn)
TABLE 12 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Bronchodilators, By Region, 2023-2030 (US$ Bn)
TABLE 13 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Beta 2-Agonists, By Region, 2017-2022 (US$ Bn)
TABLE 14 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Beta 2-Agonists, By Region, 2023-2030 (US$ Bn)
TABLE 15 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Anticholinergics, By Region, 2017-2022 (US$ Bn)
TABLE 16 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Anticholinergics, By Region, 2023-2030 (US$ Bn)
TABLE 17 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Theophyllines, By Region, 2017-2022 (US$ Bn)
TABLE 18 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Theophyllines, By Region, 2023-2030 (US$ Bn)
TABLE 19 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Phosphodiesterase Type 4 Inhibitors, By Region, 2017-2022 (US$ Bn)
TABLE 20 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Phosphodiesterase Type 4 Inhibitors, By Region, 2023-2030 (US$ Bn)
TABLE 21 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Steroids, By Region, 2017-2022 (US$ Bn)
TABLE 22 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Steroids, By Region, 2023-2030 (US$ Bn)
TABLE 23 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Others, By Region, 2017-2022 (US$ Bn)
TABLE 24 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Others, By Region, 2023-2030 (US$ Bn)
TABLE 25 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Hospital Pharmacies, By Region, 2017-2022 (US$ Bn)
TABLE 26 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Hospital Pharmacies, By Region, 2023-2030 (US$ Bn)
TABLE 27 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Retail Pharmacies, By Region, 2017-2022 (US$ Bn)
TABLE 28 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Retail Pharmacies, By Region, 2023-2030 (US$ Bn)
TABLE 29 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Online Pharmacies, By Region, 2017-2022 (US$ Bn)
TABLE 30 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Online Pharmacies, By Region, 2023-2030 (US$ Bn)
TABLE 31 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 32 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 33 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 34 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 35 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 36 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 37 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Region, 2017-2022 (US$ Bn)
TABLE 38 Global Chronic obstructive pulmonary disease (COPD) treatment Market, by Region, 2023-2030 (US$ Bn)
TABLE 39 North America Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 40 North America Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 41 North America Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 42 North America Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 43 North America Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 44 North America Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 45 North America Chronic obstructive pulmonary disease (COPD) treatment Market, by Country, 2017-2022 (US$ Bn)
TABLE 46 North America Chronic obstructive pulmonary disease (COPD) treatment Market, by Country, 2023-2030 (US$ Bn)
TABLE 47 United States Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 48 United States Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 49 United States Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 50 United States Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 51 United States Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 52 United States Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 53 Canada Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 54 Canada Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 55 Canada Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 56 Canada Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 57 Canada Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 58 Canada Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 59 Mexico Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 60 Mexico Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 61 Mexico Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 62 Mexico Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 63 Mexico Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 64 Mexico Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 65 Europe Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 66 Europe Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 67 Europe Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 68 Europe Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 69 Europe Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 70 Europe Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 71 Europe Chronic obstructive pulmonary disease (COPD) treatment Market, by Country, 2017-2022 (US$ Bn)
TABLE 72 Europe Chronic obstructive pulmonary disease (COPD) treatment Market, by Country, 2023-2030 (US$ Bn)
TABLE 73 Germany Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 74 Germany Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 75 Germany Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 76 Germany Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 77 Germany Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 78 Germany Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 79 France Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 80 France Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 81 France Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 82 France Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 83 France Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 84 France Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 85 United Kingdom Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 86 United Kingdom Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 87 United Kingdom Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 88 United Kingdom Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 89 United Kingdom Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 90 United Kingdom Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 91 Italy Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 92 Italy Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 93 Italy Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 94 Italy Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 95 Italy Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 96 Italy Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 97 Spain Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 98 Spain Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 99 Spain Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 100 Spain Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 101 Spain Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 102 Spain Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 103 Rest of Europe Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 104 Rest of Europe Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 105 Rest of Europe Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 106 Rest of Europe Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 107 Rest of Europe Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 108 Rest of Europe Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 109 Asia Pacific Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 110 Asia Pacific Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 111 Asia Pacific Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 112 Asia Pacific Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 113 Asia Pacific Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 114 Asia Pacific Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 115 Asia Pacific Chronic obstructive pulmonary disease (COPD) treatment Market, by Country, 2017-2022 (US$ Bn)
TABLE 116 Asia Pacific Chronic obstructive pulmonary disease (COPD) treatment Market, by Country, 2023-2030 (US$ Bn)
TABLE 117 China Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 118 China Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 119 China Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 120 China Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 121 China Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 122 China Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 123 Japan Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 124 Japan Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 125 Japan Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 126 Japan Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 127 Japan Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 128 Japan Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 129 India Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 130 India Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 131 India Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 132 India Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 133 India Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 134 India Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 135 South Korea Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 136 South Korea Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 137 South Korea Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 138 South Korea Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 139 South Korea Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 140 South Korea Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 141 South-East Asia Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 142 South-East Asia Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 143 South-East Asia Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 144 South-East Asia Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 145 South-East Asia Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 146 South-East Asia Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 147 Rest of Asia Pacific Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 148 Rest of Asia Pacific Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 149 Rest of Asia Pacific Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 150 Rest of Asia Pacific Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 151 Rest of Asia Pacific Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 152 Rest of Asia Pacific Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 153 Latin America Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 154 Latin America Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 155 Latin America Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 156 Latin America Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 157 Latin America Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 158 Latin America Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 159 Latin America Chronic obstructive pulmonary disease (COPD) treatment Market, by Country, 2017-2022 (US$ Bn)
TABLE 160 Latin America Chronic obstructive pulmonary disease (COPD) treatment Market, by Country, 2023-2030 (US$ Bn)
TABLE 161 Brazil Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 162 Brazil Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 163 Brazil Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 164 Brazil Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 165 Brazil Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 166 Brazil Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 167 Argentina Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 168 Argentina Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 169 Argentina Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 170 Argentina Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 171 Argentina Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 172 Argentina Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 173 Rest of Latin America Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 174 Rest of Latin America Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 175 Rest of Latin America Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 176 Rest of Latin America Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 177 Rest of Latin America Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 178 Rest of Latin America Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 179 Middle East and Africa Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 180 Middle East and Africa Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 181 Middle East and Africa Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 182 Middle East and Africa Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 183 Middle East and Africa Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 184 Middle East and Africa Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 185 Middle East and Africa Chronic obstructive pulmonary disease (COPD) treatment Market, by Country, 2017-2022 (US$ Bn)
TABLE 186 Middle East and Africa Chronic obstructive pulmonary disease (COPD) treatment Market, by Country, 2023-2030 (US$ Bn)
TABLE 187 GCC Countries Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 188 GCC Countries Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 189 GCC Countries Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 190 GCC Countries Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 191 GCC Countries Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 192 GCC Countries Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 193 South Africa Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 194 South Africa Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 195 South Africa Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 196 South Africa Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 197 South Africa Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 198 South Africa Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 199 Rest of Middle East and Africa Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 200 Rest of Middle East and Africa Chronic obstructive pulmonary disease (COPD) treatment Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 201 Rest of Middle East and Africa Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 202 Rest of Middle East and Africa Chronic obstructive pulmonary disease (COPD) treatment Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 203 Rest of Middle East and Africa Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 204 Rest of Middle East and Africa Chronic obstructive pulmonary disease (COPD) treatment Market, by Route of Administration, 2023-2030 (US$ Bn)

Frequently Asked Questions

What is the current size of the global Chronic obstructive pulmonary disease (COPD) treatment market?

The global Chronic obstructive pulmonary disease (COPD) treatment market was valued at USD 20.3 Billion in 2022.

What is the expected growth rate of the Chronic obstructive pulmonary disease (COPD) treatment market between 2023 and 2030?

The Chronic obstructive pulmonary disease (COPD) treatment market is expected to grow at a CAGR of 4.70% between 2023 and 2030, reaching USD 27.99772927 Billion in 2030.

Which drug class segment is leading the market share in terms of Drug class?

Bronchodilators is the leading segment by drug class, holding around more than three-firth of the share in value in 2022.

Which distribution channel governs the demand for Chronic obstructive pulmonary disease (COPD) treatment in the world?

Hospital Pharmacies govern the demand for Chronic obstructive pulmonary disease (COPD) treatment worldwide, holding a massive share of nearly 30% in 2022.

Which segment is expected to post the highest CAGR during the forecast period?

Anticholinergics segments are expected to post the highest CAGR during the forecast period.

Which region is fueling the growth of the Chronic obstructive pulmonary disease (COPD) treatment industry?

Asia-pacific is fueling the growth of the Chronic obstructive pulmonary disease (COPD) treatment industry, with a nearly a two-thirds share in 2022.

Who are the major players in the global Chronic obstructive pulmonary disease (COPD) treatment market?

The top players include AstraZeneca Plc, Orion Corporation, Mylan N.V., GlaxoSmithKline plc, Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., Novartis AG, Sunovion Pharmaceuticals, Inc., and others.

What is the major market driver of the Chronic obstructive pulmonary disease (COPD) treatment industry?

Rising increasing prevalence of COPD globally, particularly among the aging population & advancements in medical technologies and drug development, such as bronchodilators, anti-inflammatory drugs, and oxygen therapy are some of the major market drivers.

What are the major market restraints of the Chronic obstructive pulmonary disease (COPD) treatment industry?

Costs associated with COPD treatment, including medication, hospitalization, and long-term care & lack of awareness and underdiagnosis of COPD, and limited access to healthcare facilities, especially in rural areas, are still restraints of the chronic obstructive pulmonary disease (COPD) treatment industry.

What are the major market opportunities in the Chronic obstructive pulmonary disease (COPD) treatment industry?

Growing focus on personalized medicine and precision therapies opens doors for targeted treatment approaches in COPD management & growing adoption of digital health solutions, and telemedicine are opportunities for the Chronic obstructive pulmonary disease (COPD) treatment industry.

Purchase Options

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –